- £169.69bn
- £188.02bn
- $45.81bn
- 73
- 15
- 48
- 39
REG - AstraZeneca PLC - Beyfortus approved in US for infant RSV prevention
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Dato-DXd significantly improved PFS in lung cancer
AnnouncementREG - AstraZeneca PLC - nirsevimab recommended for infant RSV protection
AnnouncementREG - AstraZeneca PLC - AstraZeneca agreement with Quell Therapeutics
AnnouncementREG - AstraZeneca PLC - Imfinzi improved pCR in gastric and GEJ cancers
AnnouncementREG - AstraZeneca PLC - Block listing Interim Review
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Lynparza approved in US for BRCAm prostate cancer
AnnouncementREG - AstraZeneca PLC - Imfinzi + Lynparza prolonged PFS in endometrial ca
AnnouncementRCS - Neurimmune - Neurimmune: Promising NI006 Phase1 Results in NEJM
AnnouncementREG - AstraZeneca PLC - Directorate Change
AnnouncementREG - AstraZeneca PLC - Tagrisso plus chemo improved PFS in lung cancer
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - Farxiga extended in the US for heart failure
AnnouncementREG - AstraZeneca PLC - Total Voting Rights
AnnouncementREG - AstraZeneca PLC - Director/PDMR Shareholding
AnnouncementREG - AstraZeneca PLC - ODAC vote on Lynparza combo in prostate cancer
AnnouncementREG - AstraZeneca PLC - Result of AGM
Announcement